GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » EV-to-Revenue

Vifor Pharma AG (LTS:0RPD) EV-to-Revenue : 5.69 (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vifor Pharma AG's enterprise value is CHF10,375 Mil. Vifor Pharma AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 was CHF1,825 Mil. Therefore, Vifor Pharma AG's EV-to-Revenue for today is 5.69.

The historical rank and industry rank for Vifor Pharma AG's EV-to-Revenue or its related term are showing as below:

LTS:0RPD' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.23   Med: 5.86   Max: 8.85
Current: 6.02

During the past 13 years, the highest EV-to-Revenue of Vifor Pharma AG was 8.85. The lowest was 2.23. And the median was 5.86.

LTS:0RPD's EV-to-Revenue is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.29 vs LTS:0RPD: 6.02

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-27), Vifor Pharma AG's stock price is CHF165.55. Vifor Pharma AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was CHF28.06. Therefore, Vifor Pharma AG's PS Ratio for today is 5.90.


Vifor Pharma AG EV-to-Revenue Historical Data

The historical data trend for Vifor Pharma AG's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG EV-to-Revenue Chart

Vifor Pharma AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.91 5.25 6.10 5.27 5.74

Vifor Pharma AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.10 - 5.27 - 5.74

Competitive Comparison of Vifor Pharma AG's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vifor Pharma AG's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's EV-to-Revenue falls into.



Vifor Pharma AG EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vifor Pharma AG's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=10375.196/1824.6
=5.69

Vifor Pharma AG's current Enterprise Value is CHF10,375 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vifor Pharma AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 was CHF1,825 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vifor Pharma AG  (LTS:0RPD) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vifor Pharma AG's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=165.55/28.062
=5.90

Vifor Pharma AG's share price for today is CHF165.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2021 was CHF28.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vifor Pharma AG EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vifor Pharma AG (LTS:0RPD) Business Description

Traded in Other Exchanges
N/A
Address
Rechenstrasse 37, Saint Gallen, CHE, 9014
Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines